Challenges in SN38 drug delivery: current success and future directions.
about
Antibody-drug conjugates--an emerging class of cancer treatmentPreclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary.In vitro and in vivo evaluation of SN-38 nanocrystals with different particle sizes
P2860
Challenges in SN38 drug delivery: current success and future directions.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Challenges in SN38 drug delivery: current success and future directions.
@en
type
label
Challenges in SN38 drug delivery: current success and future directions.
@en
prefLabel
Challenges in SN38 drug delivery: current success and future directions.
@en
P2860
P1476
Challenges in SN38 drug delivery: current success and future directions.
@en
P2093
Srinath Palakurthi
P2860
P304
P356
10.1517/17425247.2015.1070142
P407
P577
2015-07-24T00:00:00Z